Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 9 In the USA VictozaⓇ CV indication and OzempicⓇ launch contribute to market growth and stabilising market share USA GLP-1 TRX market development Monthly USA GLP-1 volume market share NN GLP-1 VictozaⓇ OzempicⓇ Annual market growth (RHS)¹ Exenatide ER Quarterly TRX (million) Other GLP-1s OzempicⓇ Market TRX share Dulaglutide VictozaⓇ growth 60% 3.0 35% 2.5 28% 30% 40% 2.0 25% 1.5 20% 20% 1.0 15 % 0.5 0.0 10 % 0% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2016 2017 2017 2017 2017 2018 2018 2018 Source: IQVIA monthly NPA, September weekly NPA, week ending 5 October 2018 1 Growth rate three months year over year RHS: Right hand side Oct 2016 Source: IQVIA monthly NPA, August 2018; wNPA for September, week ending 5 October 2018 dulaglutide exenatide albiglutide 43.3% 43.2% 38.3% 13.0% 5.1% Sep 2018 novo nordisk

View entire presentation